Ophthalmology Times connects eye care professionals with surgery, imaging, gene therapy, & diagnostic advances to enhance ...

The trial subjects were adults with either type 1 or type 2 diabetes, exhibiting central involvement in diabetic macular ...

In this Healio Video Perspective from the ARVO meeting, Michael Javaheri, MD, overviews real-world data on Eylea HD in ...

Trial evaluated number of supplemental injections needed for the treatment of DME for patients on ILUVIEN versus the ...

ANI Pharmaceuticals (NASDAQ:ANIP) lost ~8% in the premarket on Wednesday after the company announced a failure in a clinical ...

In ANI's New Day trial, patients were randomized to an induction phase to receive either a single Iluvien injection or a series of five monthly injections of aflibercept, followed by supplemental ...

Aflibercept is a recombinant human fusion protein that acts as a soluble decoy receptor for vascular endothelial growth factor (VEGF) family members VEGF-A, VEGF-B, and placental growth factor.

Aflibercept 8mg late-breaking data presented at Retina Society in diabetic macular edema and wet age-related macular degeneration. News release. Regeneron Pharmaceuticals, Inc. November 4, 2022.

New Vabysmo Data Suggest Greater Retinal Drying Versus Aflibercept in Wet Age-Related Macular Degeneration and Diabetic Macular Edema ‒ Post-hoc analyses from four Phase III studies indicate ...

Aflibercept is clearly an option for patients who are showing an incomplete anatomic response to other anti-VEGF agents," he noted. Dr. Recchia and colleagues presented results from a series of ...

--Regeneron Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has accepted for Priority Review the Biologics License Application for aflibercept 8 mg for treatment ...

It agreed that aflibercept as well as other anti-VEGF treatments were a substantial improvement over previous treatments, and considered that this improvement applied to the class of drugs. In ...